Millions of Americans have adorned themselves with glimmering Fitbits, Jawbones, Nike Fuelbands, and Misfits, Basis, Withings, and Garmin bracelets over the years. The devices have become so mainstream even Grandma has one. Perhaps the fact that Grandma is now tracking her data means that the industry is ripe for a change.
Recently though we’ve seen the popularity of wearables wane considerably. This month Mike and Albert Lee, founders of myfitnesspal announced that they would be departing from Under Armour; and we learned that Adidas is dropping their wearables division entirely.
Why? Its a fairly easy question to answer. Under Armour spent 2017 falling from grace and it’s possible their waning interest in connected fitness is due both to financial constraints as well as a series of departures of senior-level talent including Robin Thurston (MapMyRun), and Mette Lykke (Endomondo). Looking at Adidas though, they are dropping their dedicated connected fitness division in favor of a more distributed and integrated approach.
With this shift upon us, what is next wave of innovation? Let’s look at two companies.
, the bay-area based company, collects genetics, vitals and metabolism of their customers; and uses their data and machine learning algorithms to deliver personal nutrition plans that align with the user’s health goals. Parsley Health
is redefining primary care medicine by committing their doctors to whole-body health than to quick fixes and bonuses.
WinterTech is almost one month away, and we’re extremely excited about the final agenda. The 2018 edition of WinterTech will be not only be focusing on the new investment treads in digital health, but will take a in-depth look into the revolution in choice within the consumer landscape and the rapid development of digital therapeutics.
Our jam-packed 1-day conference includes:
- Keynote presentation on how to create seamless health care experiences to meet the needs of consumers by Mark Ganz, CEO of Cambia Health.
- Panel discussion on the opportunities, roadblocks, and regulations within the field of digital therapeutics by Bakul Patel, Associate Director for Digital Health at the FDA.
- Investment Strategies Past and Present: a look into 2017 trends, surprises, and flops. plus predictions for 2018 by VC firms GE Ventures, Canaan, Fifty Years, NEA, and B Capital Group.
- Fireside chat between 4 VCs and their CEOs on their relationship and investment models
- Access to the Investor Breakfast where start-ups and investors discuss business models and explore portfolios. Start-ups apply here.
- Live demos from some of the most innovative companies in the digital healthcare space.
Don’t miss out the hottest digital healthcare event focusing on investment in the space. Register today
to take advantage of the early bird rate before prices increase after Friday, December 22nd
Imagine if you will, a future in which a cancer diagnosis will be treated with a lifestyle change, like a chronic condition. Survivable. Manageable. Like Diabetes. Sure, to receive a cancer diagnosis today does not mean what it meant twenty years ago, but we are also unlikely to reach a point of ever acting casual about the term or the treatment plan.
In the meantime though, the increasing prevalence of personal data collection is driving new approaches in care plans that have a real shot at improving quality of life. The narrative of one’s life can be seen in the data – everything from where you live, what you eat, how you workout, even what you search for on the internet. The sources of such personal data come from places like clinical trials, biosensors, and wearables and is being stored in your Electronic Medical Record.
The sticking point though is the advancement of technological tools to view, aggregate, extract, and analyze relevant data to derive a meaningful plan of attack (er, treatment plan). One interoperable tool that plugs right into the EMR is Cota Healthcare
. Pair this with omics data and genome sequencing technology, like 2bPrecise, and physicians are gaining insight into what makes you, you. And thus are better able to customize a bespoke cancer treatment plan, designed for you and only you.
Health 2.0 caught up with some of our favorite investors who have a strong pulse on what’s happening in digital health care both past and present. We talked about company evaluation, unmet needs in health care, and their biggest surprises yet.
“Pretty much all of my investments are in first time CEOs, which is not particularly what the venture capital playbook tells you to go do. But I find those people to be very hungry and largely underappreciated by the rest of the world. They’re also very willing to bash their head against a brick wall with me for a while, in order to try to succeed at something that is hard to do.”
– Bryan Roberts, Venrock on what he looks for in an investment.
“There are so “many tech people who want to work their way into health care venture capital. When I started in health care venture in 1998 you couldn’t give it away. I wonder how long it will be before the cycle ends?”
– Lisa Suennen, GE Ventures on what surprises her about the industry right now.
Catch up with Lisa Suennen, Bryan Roberts, and others at Health 2.0’s WinterTech event
on January 10, 2018
in San Francisco where you’ll hear more on investment trends, IPO, and the rise in consumer choices. Register today
for WinterTech before the early price ends.
By HEALTH 2.o SPONSORED CONTENT
We are human and we need health care. These are universal truths. Here’s another one – we are consumers. Consumers who happen to be in a constant state of adapting to new health care protocols. The advent of value-based care over fee-for-service has also seen an emergence of empowered consumers who are not only informed but savvy in their health care decision making. Where do I purchase? From who? How much does it cost? How much can I afford? When do I purchase? What if I need a specialist? The list goes on. Luckily there is an ever-growing group of people and organizations who continue to make the consumer experience streamlined, affordable, and personal. Even in the gravest of scenarios.
Although, unlike most other nations, the U.S. has only two parties worth the name, their professed doctrines compared with their actions strikes me as more confusing than the well-known Slutsky Decomposition which, as everyone knows, can be derived simply from a straightforward application of Kramer’s rule to a matrix of second partial derivatives of a multivariable demand function.
The leaders of the drug industry, for example, probably are now breaking out the champagne in the soothing belief that their aggressive pricing policies for even old drugs are safe for at least the next eight years from the allegedly fearsome, regulation-prone, price-controlling Democrats. My advice to them is: Cool it! Follow me through a brief history of Republican health policy, to learn what Republicans will do to the health-care sector when it ticks them off.
Republicans like to tar Democrats over allegedly socialist policy instruments such as price controls, global budgets and deficit-financed government spending. Democrats usually roll over to take that abuse, almost like hanging onto their posteriors signs that says “Kick me.” I say “abuse,” because Republicans have never shied away from using the Democrats’ allegedly left-wing tactics when health care chews up their budgets or turns voters against them.
Uwe Reinhardt, Princeton economist and one of the best known and best loved personalities in the health policy world died today. I join the rest of the health policy community in mourning the passing of the master explainer and wit that Uwe was.
But I also remember a small act of his kindness. The first time I met him I was a little late joining a crowd trying to get his attention after a keynote. He had talked to many, and had to go. But as he was being hustled off by his handlers, he realized he hadn’t talked to me, and he walked back to do an introduction and share a few words. He was already the biggest celebrity in our little world, and he was clearly running late for his next appointment. He didn’t know me, yet was prepared to spend the extra moment to make me feel included. And in all our future interactions over the next 2 decades, he was the same way.
It’s clear that it was the same for everyone he knew and it’s why the grief and shock in our community is so heartfelt.
John & I are very proud that in recent years Uwe offered to write some original pieces for our little blog, and we will be running a few of them in the next few days.
RIP and thank you Uwe, and we send our condolences to his wife Mae and their daughter and son–Matthew Holt
Most people have no way of accessing DNA-powered insights about themselves, and no way to store and use their genome in ways that they control. Technology for Precision Health Summit
solves that by providing the world’s first online store for DNA-powered products
where people can explore diverse and uniquely personalized products developed by high-quality partners. After being sequenced once with true next-generation sequencing, the user can query their data on-demand at any time for a large variety of uses.
The costs of DNA sequencing have dropped rapidly, and our understanding of how DNA influences our lives has increased. For partners in the Helix marketplace, DNA now becomes a software problem, not a hardware problem, where a full clinical-grade exome is accessible through an API. Helix handles sample collection, DNA sequencing, and secure data storage so that our partners can integrate DNA insights into products across a range of categories, including ancestry, entertainment, family, fitness, health and nutrition.
for the Technology for Precision Health Summit.